Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + IBI310 + lenvatinib
- Development stage
- Phase 2
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination regimen consists of sintilimab, an anti-PD-1 monoclonal antibody; IBI310, an anti-CTLA-4 monoclonal antibody; and lenvatinib, a multi-kinase inhibitor. It is currently being evaluated in a Phase 2 clinical trial (NCT05534282) sponsored by Peking University for the treatment of non-metastatic gastric or colon cancers that are mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H). The therapeutic strategy aims for organ preservation by utilizing an initial phase of PD-1/PD-L1 antibody monotherapy followed by an intensive combination of the three agents to achieve a complete clinical response, thereby potentially avoiding the need for radical surgery. Sintilimab and IBI310 are developed by Innovent Biologics, while lenvatinib is developed by Eisai.
- Other names
- sintilimab + IBI310 + lenvatinib combination therapy
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on sintilimab + IBI310 + lenvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + IBI310 + lenvatinib.